The largest life sciences association in the state recognized those driving discovery during its 32nd annual dinner meeting ...
After the rejection of Lykos Therapeutics’ MDMA-based PTSD treatment tempered excitement for psychedelic therapeutics, a ...
FDA's rejection of MDMA therapy for PTSD doesn't dampen hopes for other psychedelic treatments. Read more here.
Spravato® is offered to treat adults with treatment-resistant depression and depressive symptoms in adults with MDD with suicidal thoughts or actions. Greenbrook has provided more than 1.68 million ...
In a Phase IIb trial, GH001 elicited significant drops in treatment-resistant depression. The news comes less than two weeks ...
The Food and Drug Administration recently expanded approval for Spravato, an antidepressant nasal spray used to treat depression.
Health Canada approved a prescription esketamine nasal spray called Spravato in 2020 to help with treatment-resistant depression. Brandi Martin, a nurse practitioner at NuVista, holds the device used ...
A nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with ...
Typically, the only ketamine-derived treatment for depression that insurance will cover is the FDA-approved nasal spray esketamine (Spravato). Because the FDA hasn't approved IV ketamine for ...
Gregory Mattingly, MD, president, Midwest Research Group, founding partner, St. Charles Psychiatric Associates, discusses the immediate impact Spravato has had on patients with treatment-resistant ...
An estimated 21 million American adults suffer from clinical depression. © 2025 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes ...
Spravato (esketamine) was approved by the EMA in December as an adjunctive, add-on therapy for people with serious depression who don’t respond to treatment with at least two from the current ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results